News Release - Eli Lilly and Company
WEBAug 27, 2024 — Zepbound is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
News Release - Eli Lilly and Company
WEBNov 8, 2023 — Lilly continues to invest in the expansion of its global manufacturing footprint to address the expected demand for innovative new treatments, like Zepbound, and help ensure the safe and reliable supply of its medicines.
News Release - Eli Lilly and Company
WEBJun 20, 2024 — Lilly has identified fake or counterfeit products that are advertised or designed to look like Lilly’s genuine FDA-approved Mounjaro ® and Zepbound ® These products are often advertised and sold online, through social media, or at certain med-spas. They are never safe to use.
News Release - Eli Lilly and Company
WEBMay 24, 2024 — This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound ® (tirzepatide) injection and Mounjaro ® (tirzepatide) injection so that more adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments.
News Release - Eli Lilly and Company
WEBMay 14, 2024 — Lilly has discovered products claiming to be compounded tirzepatide medicines that contain bacteria, high impurity levels, different chemical structures, and different colors than Mounjaro ® or Zepbound ®. In at least one instance, the product was nothing more than sugar alcohol.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, April 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in …
News Release - Eli Lilly and Company
WEBDec 11, 2023 — Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
News Release - Eli Lilly and Company
WEBMar 7, 2024 — Lilly does not promote or encourage use of Mounjaro, Zepbound, or any Lilly medicines outside of a medicine’s FDA-approved indication. Mounjaro is indicated in addition to diet and exercise to improve glycemic control in adults with type 2 …